JP2012522803A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012522803A5 JP2012522803A5 JP2012503725A JP2012503725A JP2012522803A5 JP 2012522803 A5 JP2012522803 A5 JP 2012522803A5 JP 2012503725 A JP2012503725 A JP 2012503725A JP 2012503725 A JP2012503725 A JP 2012503725A JP 2012522803 A5 JP2012522803 A5 JP 2012522803A5
- Authority
- JP
- Japan
- Prior art keywords
- salt
- composition
- crystalline form
- ornithine
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 24
- 238000000034 method Methods 0.000 claims 16
- LRSYFEZBIMVWRY-VWMHFEHESA-N (2s)-2,5-diaminopentanoic acid;2-phenylacetic acid Chemical compound NCCC[C@H](N)C(O)=O.OC(=O)CC1=CC=CC=C1 LRSYFEZBIMVWRY-VWMHFEHESA-N 0.000 claims 14
- 238000000634 powder X-ray diffraction Methods 0.000 claims 10
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical class NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 6
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 claims 5
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 3
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 claims 3
- -1 alkali metal salt Chemical class 0.000 claims 3
- 230000001965 increasing effect Effects 0.000 claims 3
- 238000002844 melting Methods 0.000 claims 3
- 230000008018 melting Effects 0.000 claims 3
- 229940049953 phenylacetate Drugs 0.000 claims 3
- 239000005711 Benzoic acid Substances 0.000 claims 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- 206010020575 Hyperammonaemia Diseases 0.000 claims 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 claims 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 claims 2
- 229910052783 alkali metal Inorganic materials 0.000 claims 2
- 235000010233 benzoic acid Nutrition 0.000 claims 2
- JQVDAXLFBXTEQA-UHFFFAOYSA-N dibutylamine Chemical compound CCCCNCCCC JQVDAXLFBXTEQA-UHFFFAOYSA-N 0.000 claims 2
- 229910052709 silver Inorganic materials 0.000 claims 2
- 239000004332 silver Substances 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- APJYDQYYACXCRM-UHFFFAOYSA-N tryptamine Chemical compound C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 claims 2
- UIQPERPLCCTBGX-UHFFFAOYSA-N 2-phenylacetic acid;silver Chemical compound [Ag].OC(=O)CC1=CC=CC=C1 UIQPERPLCCTBGX-UHFFFAOYSA-N 0.000 claims 1
- CSDQQAQKBAQLLE-UHFFFAOYSA-N 4-(4-chlorophenyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine Chemical compound C1=CC(Cl)=CC=C1C1C(C=CS2)=C2CCN1 CSDQQAQKBAQLLE-UHFFFAOYSA-N 0.000 claims 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 claims 1
- 229910000019 calcium carbonate Inorganic materials 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 208000007386 hepatic encephalopathy Diseases 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229960003104 ornithine Drugs 0.000 claims 1
- 239000003002 pH adjusting agent Substances 0.000 claims 1
- 229960003424 phenylacetic acid Drugs 0.000 claims 1
- 239000003279 phenylacetic acid Substances 0.000 claims 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 claims 1
- 239000002244 precipitate Substances 0.000 claims 1
- 238000003825 pressing Methods 0.000 claims 1
- CLDWGXZGFUNWKB-UHFFFAOYSA-M silver;benzoate Chemical group [Ag+].[O-]C(=O)C1=CC=CC=C1 CLDWGXZGFUNWKB-UHFFFAOYSA-M 0.000 claims 1
- 229910000029 sodium carbonate Inorganic materials 0.000 claims 1
- 239000012312 sodium hydride Substances 0.000 claims 1
- 229910000104 sodium hydride Inorganic materials 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16667609P | 2009-04-03 | 2009-04-03 | |
| US61/166,676 | 2009-04-03 | ||
| PCT/US2010/029708 WO2010115055A1 (en) | 2009-04-03 | 2010-04-01 | L-ornithine phenyl acetate and methods of making thereof |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015031199A Division JP6010154B2 (ja) | 2009-04-03 | 2015-02-20 | Ｌ−オルニチンフェニルアセテートおよびその製造方法 |
| JP2016237164A Division JP6328737B2 (ja) | 2009-04-03 | 2016-12-07 | Ｌ−オルニチンフェニルアセテートおよびその製造方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012522803A JP2012522803A (ja) | 2012-09-27 |
| JP2012522803A5 true JP2012522803A5 (https=) | 2013-05-16 |
| JP6144488B2 JP6144488B2 (ja) | 2017-06-07 |
Family
ID=42828717
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012503725A Active JP6144488B2 (ja) | 2009-04-03 | 2010-04-01 | Ｌ−オルニチンフェニルアセテートおよびその製造方法 |
| JP2015031199A Active JP6010154B2 (ja) | 2009-04-03 | 2015-02-20 | Ｌ−オルニチンフェニルアセテートおよびその製造方法 |
| JP2016237164A Active JP6328737B2 (ja) | 2009-04-03 | 2016-12-07 | Ｌ−オルニチンフェニルアセテートおよびその製造方法 |
| JP2018079490A Expired - Fee Related JP6647336B2 (ja) | 2009-04-03 | 2018-04-18 | Ｌ−オルニチンフェニルアセテートおよびその製造方法 |
| JP2020003346A Active JP7086118B2 (ja) | 2009-04-03 | 2020-01-14 | Ｌ－オルニチンフェニルアセテートおよびその製造方法 |
| JP2022049427A Pending JP2022088504A (ja) | 2009-04-03 | 2022-03-25 | Ｌ－オルニチンフェニルアセテートおよびその製造方法 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015031199A Active JP6010154B2 (ja) | 2009-04-03 | 2015-02-20 | Ｌ−オルニチンフェニルアセテートおよびその製造方法 |
| JP2016237164A Active JP6328737B2 (ja) | 2009-04-03 | 2016-12-07 | Ｌ−オルニチンフェニルアセテートおよびその製造方法 |
| JP2018079490A Expired - Fee Related JP6647336B2 (ja) | 2009-04-03 | 2018-04-18 | Ｌ−オルニチンフェニルアセテートおよびその製造方法 |
| JP2020003346A Active JP7086118B2 (ja) | 2009-04-03 | 2020-01-14 | Ｌ－オルニチンフェニルアセテートおよびその製造方法 |
| JP2022049427A Pending JP2022088504A (ja) | 2009-04-03 | 2022-03-25 | Ｌ－オルニチンフェニルアセテートおよびその製造方法 |
Country Status (26)
| Country | Link |
|---|---|
| US (9) | US8173706B2 (https=) |
| EP (4) | EP3263100B1 (https=) |
| JP (6) | JP6144488B2 (https=) |
| KR (6) | KR102217081B1 (https=) |
| CN (3) | CN106810464B (https=) |
| AU (1) | AU2010232521B2 (https=) |
| BR (1) | BRPI1013657A2 (https=) |
| CA (5) | CA2998344C (https=) |
| CY (1) | CY1119843T1 (https=) |
| DK (3) | DK2413924T3 (https=) |
| EA (2) | EA023051B1 (https=) |
| ES (3) | ES2928586T3 (https=) |
| HR (2) | HRP20221232T8 (https=) |
| HU (2) | HUE035921T2 (https=) |
| IL (2) | IL215449B (https=) |
| LT (2) | LT3686183T (https=) |
| MX (4) | MX356608B (https=) |
| NO (1) | NO2413924T3 (https=) |
| NZ (3) | NZ619235A (https=) |
| PL (2) | PL2413924T3 (https=) |
| PT (2) | PT2413924T (https=) |
| SG (3) | SG174982A1 (https=) |
| SI (1) | SI2413924T1 (https=) |
| SM (2) | SMT202200395T1 (https=) |
| WO (1) | WO2010115055A1 (https=) |
| ZA (1) | ZA201107189B (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2153870T1 (sl) | 2004-11-26 | 2014-05-30 | Ucl Business Plc | Sestavki, ki obsegajo ornitin in fenilacetat ali fenilbutirat, za zdravljenje hepatitične encefalopatije |
| HUE035921T2 (en) | 2009-04-03 | 2018-05-28 | Ocera Therapeutics Inc | L-ornithine phenyl acetate and methods of making thereof |
| CN104434894A (zh) | 2009-06-08 | 2015-03-25 | Ucl商业有限公司 | 使用l-鸟氨酸苯乙酸盐治疗门静脉高压和恢复肝功能 |
| US8068011B1 (en) | 2010-08-27 | 2011-11-29 | Q Street, LLC | System and method for interactive user-directed interfacing between handheld devices and RFID media |
| US8946473B2 (en) | 2010-10-06 | 2015-02-03 | Ocera Therapeutics, Inc. | Methods of making L-ornithine phenyl acetate |
| CN102993037B (zh) * | 2012-11-20 | 2015-03-04 | 南京工业大学 | 一种l-鸟氨酸苯乙酸盐的制备方法 |
| CN105481725B (zh) * | 2014-09-18 | 2019-01-22 | 博瑞生物医药（苏州）股份有限公司 | L-精氨酸苯乙酸盐的晶型及其制备方法 |
| ES2769000T3 (es) | 2014-11-24 | 2020-06-24 | Ucl Business Ltd | Tratamiento de enfermedades asociadas con la activación de células estrelladas hepáticas utilizando terapias reductoras de amoníaco |
| CN107708684A (zh) | 2015-04-20 | 2018-02-16 | 欧塞拉治疗有限公司 | L‑鸟氨酸苯乙酸盐制剂 |
| WO2017031131A1 (en) | 2015-08-18 | 2017-02-23 | Ocera Therapeutics, Inc. | Treatment and prevention of muscle loss using l-ornithine in combination with at least one of phenylacetate and phenylbutyrate |
| HK1257679A1 (zh) * | 2015-09-25 | 2019-10-25 | Ocera Therapeutics, Inc. | 使用l-鸟苷酸与苯乙酸根和苯基丁酸根中至少一种的结合治疗和预防神经元细胞损失 |
| US11219611B2 (en) | 2015-11-13 | 2022-01-11 | Ocera Therapeutics, Inc. | Formulations of L-ornithine phenylacetate |
| CN108366983A (zh) | 2015-11-13 | 2018-08-03 | 欧塞拉治疗有限公司 | L-鸟氨酸苯乙酸盐制剂 |
| JOP20190146A1 (ar) | 2016-12-19 | 2019-06-18 | Axcella Health Inc | تركيبات حمض أميني وطرق لمعالجة أمراض الكبد |
| MX389665B (es) | 2017-05-11 | 2025-03-20 | Ocera Therapeutics Inc | Procesos para producir fenilacetato de l-ornitina |
| MX2020001765A (es) | 2017-08-14 | 2020-07-29 | Axcella Health Inc | Composiciones de aminoacidos para el tratamiento de enfermedad hepatica. |
| CN112839643A (zh) | 2018-06-20 | 2021-05-25 | 胺细拉健康公司 | 用于治疗肌肉中脂肪浸润的组合物及方法 |
| SG11202111509PA (en) | 2019-05-09 | 2021-11-29 | Ocera Therapeutics Inc | Methods of assessing and treating hepatic encephalopathy |
| CN110707221B (zh) * | 2019-09-25 | 2023-09-01 | 北京大学深圳研究生院 | 氨基酸离子液体在制备钙钛矿光电器件中钙钛矿层的应用 |
| PH12022550738A1 (en) * | 2019-10-16 | 2023-05-08 | Mallinckrodt Entpr Llc | Dosages and uses of ornithine phenylacetate for treating hyperammonemia |
| WO2023240081A1 (en) * | 2022-06-06 | 2023-12-14 | Yale University | Treatment, amelioration, and/or prevention of inflammatory and autoimmune diseases |
| WO2024261477A1 (en) | 2023-06-20 | 2024-12-26 | Yaqrit Limited | Combination of tlr4 antagonist, ornithine and phenylacetate or phenylbutyrate |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB965637A (en) | 1962-04-23 | 1964-08-06 | Tanabe Seiyaku Co | L-ornithine l-aspartate |
| NL302572A (https=) | 1962-12-27 | |||
| GB1067742A (en) | 1963-09-16 | 1967-05-03 | Kyowa Hakko Kogyo Kk | Process for the preparation of l-ornithine l-aspartate |
| ZA716628B (en) | 1970-10-15 | 1972-06-28 | Richardson Merrell Spa | Composition and method for treatment of hepatic disease and mental fatigue |
| FR2113774A1 (en) | 1970-11-13 | 1972-06-30 | Roques Ets | Prepn of l-ornithine salts with org acids - using silver oxides |
| US4100293A (en) | 1974-04-15 | 1978-07-11 | The Johns Hopkins University | Treatment of hepatic disorders with therapeutic compositions comprising keto analogs of essential amino acids |
| US3950529A (en) | 1975-02-03 | 1976-04-13 | Massachusetts General Hospital | Amino acid formulations for patients with liver disease and method of using same |
| US4320146A (en) | 1978-03-17 | 1982-03-16 | The Johns Hopkins University | Treatment of hepatic and renal disorders with ornithine and arginine salts of branched chain keto acids |
| US4228099A (en) | 1978-03-17 | 1980-10-14 | The Johns Hopkins University | Ornithine and arginine salts of branched chain keto acids and uses in treatment of hepatic and renal disorders |
| US4352814A (en) | 1979-04-18 | 1982-10-05 | The Johns Hopkins University | Treatment of hepatic and renal disorders with mixed salts of essential or semi-essential amino acids and nitrogen-free analogs |
| US4284647A (en) | 1980-03-31 | 1981-08-18 | The Johns Hopkins University | Process for waste nitrogen removal |
| US4457942A (en) | 1982-08-20 | 1984-07-03 | Brusilow Saul W | Process for waste nitrogen removal |
| US4857555A (en) | 1985-09-12 | 1989-08-15 | Brigham & Women's Hospital | Method of treating catabolic dysfunction |
| US4783443A (en) | 1986-03-03 | 1988-11-08 | The University Of Chicago | Amino acyl cephalosporin derivatives |
| US5139981A (en) | 1987-06-24 | 1992-08-18 | Union Carbide Chemicals & Plastics Technology Corporation | Process for preparing silver(I)-exchanged resins |
| JP2522034B2 (ja) | 1988-12-27 | 1996-08-07 | 味の素株式会社 | α−ケト酸・アミノ酸塩化合物及びその製造方法 |
| JPH03273578A (ja) | 1990-03-23 | 1991-12-04 | Ricoh Co Ltd | 対物レンズクリーニング装置 |
| DE4020980C1 (https=) * | 1990-07-02 | 1991-09-26 | Degussa Ag, 6000 Frankfurt, De | |
| US5591613A (en) | 1990-07-02 | 1997-01-07 | Degussa Aktiengesellschaft | Method for the preparation of D-arginine and L-ornithine |
| JP3127484B2 (ja) | 1991-02-28 | 2001-01-22 | 味の素株式会社 | 肝炎治療薬 |
| US5767086A (en) | 1992-04-03 | 1998-06-16 | Terrapin Technologies, Inc. | Bone marrow stimulation by certain glutathione analogs |
| JP3166123B2 (ja) | 1992-09-09 | 2001-05-14 | フアイソンズ・ピーエルシー | 薬剤パッケージング |
| US5571783A (en) | 1993-03-09 | 1996-11-05 | Clintec Nutrition Company | Composition and method for treating patients with hepatic disease |
| JP3273578B2 (ja) | 1993-09-21 | 2002-04-08 | 第一化学薬品株式会社 | オルニチンと酸性アミノ酸類又はケト酸類との塩の製造法 |
| US5840891A (en) | 1994-07-28 | 1998-11-24 | Syntex (U.S.A.) Inc. | 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol derivative |
| IL116674A (en) | 1995-01-09 | 2003-05-29 | Mendell Co Inc Edward | Microcrystalline cellulose-based excipient having improved compressibility, pharmaceutical compositions containing the same and methods for the preparation of said excipient and of solid dosage form thereof |
| WO1997030167A1 (en) | 1996-02-13 | 1997-08-21 | The Trustees Of The University Of Pennsylvania | Method of treating liver disorders |
| ZA986614B (en) | 1997-07-25 | 1999-01-27 | Gilead Sciences | Nucleotide analog composition |
| GB9815567D0 (en) | 1998-07-18 | 1998-09-16 | Glaxo Group Ltd | Antiviral compound |
| US6258849B1 (en) | 1998-07-23 | 2001-07-10 | Stanislaw R. Burzynski | Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate |
| CA2374273A1 (en) | 1999-05-21 | 2000-11-30 | Takeda Chemical Industries, Ltd. | Liver function controlling agents |
| US6768024B1 (en) | 2000-08-04 | 2004-07-27 | Lion Bioscience Ag | Triamine derivative melanocortin receptor ligands and methods of using same |
| JP3211824B1 (ja) | 2000-10-26 | 2001-09-25 | 味の素株式会社 | 分岐鎖アミノ酸含有医薬用顆粒製剤とその製造方法 |
| JPWO2002074302A1 (ja) | 2001-03-15 | 2005-07-14 | 独立行政法人理化学研究所 | 肝機能障害改善用アミノ酸組成物 |
| US6503530B1 (en) | 2001-11-01 | 2003-01-07 | Chunghee Kimberly Kang | Method of preventing development of severe metabolic derangement in inborn errors of metabolism |
| US20030105104A1 (en) | 2001-11-27 | 2003-06-05 | Burzynski Stanislaw R. | Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy |
| US20040229948A1 (en) | 2002-04-12 | 2004-11-18 | Summar Marshall L. | Method for preventing hepatic encephalopathic episodes |
| US20030195255A1 (en) | 2002-04-12 | 2003-10-16 | Summar Marshall L. | Method for treating hepatic encephalopathies |
| CN1383815A (zh) | 2002-05-08 | 2002-12-11 | 刘万忠 | 防治肝病、肝性脑病的鸟氨酸和门冬氨酸的复方制剂及其制备方法 |
| US20040152784A1 (en) | 2002-07-23 | 2004-08-05 | Special Products Limited | Pharmaceutical composition and method for treatment of a urea cycle deficiency or sickle-cell anaemia |
| JPWO2004019928A1 (ja) | 2002-08-30 | 2005-12-15 | 味の素株式会社 | 肝疾患治療剤 |
| US20050059150A1 (en) * | 2003-09-17 | 2005-03-17 | Becton, Dickinson And Company | Environments that maintain function of primary liver cells |
| MXPA03009902A (es) * | 2003-10-29 | 2005-05-03 | Manuel Francisco Lara Och Jose | Compuestos para reducir la hiperamonemia en pacientes con cirrosis u otras incapacidad para la eliminacion de amonio. |
| CA2556752C (en) * | 2004-02-23 | 2016-02-02 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| US7589235B2 (en) * | 2004-05-06 | 2009-09-15 | Osteologix, A/S | High yield and rapid synthesis methods for producing metallo-organic salts |
| WO2006059237A1 (en) | 2004-08-30 | 2006-06-08 | Lunamed, Inc. | 4-phenylbutyric acid controlled-release formulations for therapeutic use |
| GB0426141D0 (en) * | 2004-11-26 | 2004-12-29 | Ucl Biomedica Plc | Treatment |
| SI2153870T1 (sl) * | 2004-11-26 | 2014-05-30 | Ucl Business Plc | Sestavki, ki obsegajo ornitin in fenilacetat ali fenilbutirat, za zdravljenje hepatitične encefalopatije |
| HRP20140476T1 (hr) | 2005-11-17 | 2014-07-18 | Silverstone Pharma Est. | Stabilni oblik amorfnih soli perindoprila, postupak njihove pripreme, posebno industrijske pripreme i njihova uporaba u lijeäśenju hipertenzije |
| JPWO2007077995A1 (ja) | 2006-01-05 | 2009-06-11 | 協和発酵バイオ株式会社 | 筋肉増量剤 |
| DE102007009243A1 (de) | 2007-02-22 | 2008-09-18 | Evonik Röhm Gmbh | Pellets mit einer Wirkstoff-Matrix und einem Polymerüberzug, sowie ein Verfahren zur Herstellung der Pellets |
| WO2009149196A1 (en) | 2008-06-04 | 2009-12-10 | Phenolics, Llc. | Enteric-coated formulations of polyethylene glycol and one or more soluble amino acids for oral ingestion and enhanced uptake of same |
| HUE035921T2 (en) | 2009-04-03 | 2018-05-28 | Ocera Therapeutics Inc | L-ornithine phenyl acetate and methods of making thereof |
| AU2015221466B2 (en) | 2009-04-03 | 2017-02-02 | Ocera Therapeutics, Inc. | L-ornithine phenyl acetate and methods of making thereof |
| CA2763894A1 (en) | 2009-06-02 | 2011-01-13 | Salix Pharmaceuticals, Ltd. | Use of rifaximin to maintain remission of hepatic encephalopathy |
| CN104434894A (zh) | 2009-06-08 | 2015-03-25 | Ucl商业有限公司 | 使用l-鸟氨酸苯乙酸盐治疗门静脉高压和恢复肝功能 |
| AU2014250643B2 (en) | 2009-06-08 | 2016-07-14 | Ocera Therapeutics, Inc. | Treatment of portal hypertension and restoration of liver function using L-ornithine phenylacetate |
| JP2011236160A (ja) | 2010-05-11 | 2011-11-24 | Shinshu Univ | 非アルコール性肝疾患治療薬 |
| US8946473B2 (en) | 2010-10-06 | 2015-02-03 | Ocera Therapeutics, Inc. | Methods of making L-ornithine phenyl acetate |
| PT2922576T (pt) | 2012-11-21 | 2018-01-24 | Horizon Therapeutics Llc | Métodos de administração e avaliação de fármacos sequestradores de azoto para o tratamento de encefalopatia hepática |
| CN103705490B (zh) | 2013-10-31 | 2016-08-17 | 蚌埠丰原医药科技发展有限公司 | 一种门冬氨酸鸟氨酸的缓释制剂及其制备工艺 |
| ES2769000T3 (es) | 2014-11-24 | 2020-06-24 | Ucl Business Ltd | Tratamiento de enfermedades asociadas con la activación de células estrelladas hepáticas utilizando terapias reductoras de amoníaco |
| CN107708684A (zh) | 2015-04-20 | 2018-02-16 | 欧塞拉治疗有限公司 | L‑鸟氨酸苯乙酸盐制剂 |
| WO2017031131A1 (en) | 2015-08-18 | 2017-02-23 | Ocera Therapeutics, Inc. | Treatment and prevention of muscle loss using l-ornithine in combination with at least one of phenylacetate and phenylbutyrate |
| HK1257679A1 (zh) | 2015-09-25 | 2019-10-25 | Ocera Therapeutics, Inc. | 使用l-鸟苷酸与苯乙酸根和苯基丁酸根中至少一种的结合治疗和预防神经元细胞损失 |
| US11219611B2 (en) | 2015-11-13 | 2022-01-11 | Ocera Therapeutics, Inc. | Formulations of L-ornithine phenylacetate |
| MX389665B (es) | 2017-05-11 | 2025-03-20 | Ocera Therapeutics Inc | Procesos para producir fenilacetato de l-ornitina |
| SG11202111509PA (en) | 2019-05-09 | 2021-11-29 | Ocera Therapeutics Inc | Methods of assessing and treating hepatic encephalopathy |
| PH12022550738A1 (en) | 2019-10-16 | 2023-05-08 | Mallinckrodt Entpr Llc | Dosages and uses of ornithine phenylacetate for treating hyperammonemia |
| EP4153162A4 (en) | 2020-05-22 | 2024-06-05 | Ocera Therapeutics, Inc. | USES OF ORNITHINE PHENYLACETATE FOR THE TREATMENT OF HYPERAMMONEMIA |
-
2010
- 2010-04-01 HU HUE10759442A patent/HUE035921T2/en unknown
- 2010-04-01 SG SG2011071164A patent/SG174982A1/en unknown
- 2010-04-01 MX MX2014008993A patent/MX356608B/es unknown
- 2010-04-01 SI SI201031596T patent/SI2413924T1/en unknown
- 2010-04-01 KR KR1020207016586A patent/KR102217081B1/ko not_active Expired - Fee Related
- 2010-04-01 KR KR1020227016294A patent/KR20220067001A/ko not_active Abandoned
- 2010-04-01 LT LTEP20161306.4T patent/LT3686183T/lt unknown
- 2010-04-01 CN CN201710053850.1A patent/CN106810464B/zh active Active
- 2010-04-01 NZ NZ619235A patent/NZ619235A/en unknown
- 2010-04-01 HR HRP20221232TT patent/HRP20221232T8/hr unknown
- 2010-04-01 PL PL10759442T patent/PL2413924T3/pl unknown
- 2010-04-01 EP EP17185173.6A patent/EP3263100B1/en active Active
- 2010-04-01 MX MX2018006692A patent/MX375111B/es unknown
- 2010-04-01 MX MX2011010262A patent/MX2011010262A/es active IP Right Grant
- 2010-04-01 KR KR1020187008530A patent/KR101975726B1/ko active Active
- 2010-04-01 CA CA2998344A patent/CA2998344C/en active Active
- 2010-04-01 SG SG10202010988WA patent/SG10202010988WA/en unknown
- 2010-04-01 JP JP2012503725A patent/JP6144488B2/ja active Active
- 2010-04-01 EP EP22185562.0A patent/EP4101838A1/en active Pending
- 2010-04-01 BR BRPI1013657A patent/BRPI1013657A2/pt not_active Application Discontinuation
- 2010-04-01 EP EP10759442.6A patent/EP2413924B1/en active Active
- 2010-04-01 MX MX2020009699A patent/MX388894B/es unknown
- 2010-04-01 PT PT107594426T patent/PT2413924T/pt unknown
- 2010-04-01 CA CA2998434A patent/CA2998434C/en active Active
- 2010-04-01 EP EP20161306.4A patent/EP3686183B1/en active Active
- 2010-04-01 SM SM20220395T patent/SMT202200395T1/it unknown
- 2010-04-01 SM SM20170601T patent/SMT201700601T1/it unknown
- 2010-04-01 KR KR1020117026256A patent/KR101844605B1/ko active Active
- 2010-04-01 ES ES20161306T patent/ES2928586T3/es active Active
- 2010-04-01 DK DK10759442.6T patent/DK2413924T3/en active
- 2010-04-01 PT PT201613064T patent/PT3686183T/pt unknown
- 2010-04-01 ES ES17185173T patent/ES2791524T3/es active Active
- 2010-04-01 CN CN201410392027.XA patent/CN104230730B/zh active Active
- 2010-04-01 NZ NZ595706A patent/NZ595706A/en unknown
- 2010-04-01 CN CN201080021311.6A patent/CN102421432B/zh active Active
- 2010-04-01 AU AU2010232521A patent/AU2010232521B2/en active Active
- 2010-04-01 KR KR1020197012203A patent/KR102123243B1/ko active Active
- 2010-04-01 EA EA201171216A patent/EA023051B1/ru not_active IP Right Cessation
- 2010-04-01 PL PL20161306.4T patent/PL3686183T3/pl unknown
- 2010-04-01 DK DK20161306.4T patent/DK3686183T3/da active
- 2010-04-01 NO NO10759442A patent/NO2413924T3/no unknown
- 2010-04-01 EA EA201500650A patent/EA034409B1/ru not_active IP Right Cessation
- 2010-04-01 HU HUE20161306A patent/HUE060371T2/hu unknown
- 2010-04-01 WO PCT/US2010/029708 patent/WO2010115055A1/en not_active Ceased
- 2010-04-01 DK DK17185173.6T patent/DK3263100T3/da active
- 2010-04-01 ES ES10759442.6T patent/ES2652187T3/es active Active
- 2010-04-01 CA CA3205755A patent/CA3205755A1/en active Pending
- 2010-04-01 SG SG10201406300YA patent/SG10201406300YA/en unknown
- 2010-04-01 KR KR1020217004211A patent/KR102399540B1/ko active Active
- 2010-04-01 LT LTEP10759442.6T patent/LT2413924T/lt unknown
- 2010-04-01 HR HRP20171962TT patent/HRP20171962T1/hr unknown
- 2010-04-01 CA CA3077846A patent/CA3077846C/en active Active
- 2010-04-01 NZ NZ708458A patent/NZ708458A/en unknown
- 2010-04-01 CA CA2757373A patent/CA2757373C/en active Active
- 2010-04-02 US US12/753,763 patent/US8173706B2/en not_active Expired - Fee Related
-
2011
- 2011-09-30 ZA ZA2011/07189A patent/ZA201107189B/en unknown
- 2011-10-02 IL IL215449A patent/IL215449B/en active IP Right Grant
-
2012
- 2012-03-30 US US13/436,642 patent/US8492439B2/en active Active
-
2013
- 2013-07-08 US US13/937,107 patent/US8785498B2/en active Active
-
2014
- 2014-06-09 US US14/299,940 patent/US9034925B2/en active Active
-
2015
- 2015-02-20 JP JP2015031199A patent/JP6010154B2/ja active Active
- 2015-05-18 US US14/715,481 patent/US9604909B2/en active Active
-
2016
- 2016-12-07 JP JP2016237164A patent/JP6328737B2/ja active Active
-
2017
- 2017-03-24 US US15/469,359 patent/US10173964B2/en active Active
- 2017-12-20 CY CY20171101334T patent/CY1119843T1/el unknown
-
2018
- 2018-04-18 JP JP2018079490A patent/JP6647336B2/ja not_active Expired - Fee Related
- 2018-07-17 US US16/037,655 patent/US10550069B2/en active Active
- 2018-12-18 IL IL263784A patent/IL263784A/en unknown
-
2020
- 2020-01-14 JP JP2020003346A patent/JP7086118B2/ja active Active
- 2020-01-31 US US16/778,696 patent/US11161802B2/en active Active
-
2021
- 2021-11-01 US US17/516,591 patent/US12516015B2/en active Active
-
2022
- 2022-03-25 JP JP2022049427A patent/JP2022088504A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012522803A5 (https=) | ||
| JP2013542935A5 (https=) | ||
| RU2014110399A (ru) | Кристаллические формы вгс протеазного ингибитора | |
| JP2014524442A5 (https=) | ||
| NZ742200A (en) | Treatment of osteoarthritis | |
| JP2015510010A5 (https=) | ||
| JP2009517023A5 (https=) | ||
| JP2012512197A5 (https=) | ||
| JP2017522276A5 (https=) | ||
| JP2015535287A5 (https=) | ||
| NZ596872A (en) | Improved method for synthesizing pirfenidone | |
| HRP20140666T1 (hr) | Kristalni oblici derivata 2-tiazolil-4-kinolinil-oksi, snažnog hcv-inhibitora | |
| SI2413924T1 (en) | L-ornithine phenyl acetate and methods of making thereof | |
| JP2012528883A5 (https=) | ||
| JP2013538849A5 (https=) | ||
| TN2011000597A1 (en) | Non-caking salt composition, preparation process and use thereof | |
| GEP20094576B (en) | New cyrstalline form iii of agomelatine, a process for its preparation and pharmaceutical compositions containing it | |
| CN107129432B (zh) | 一种紫外线吸收剂4,4’－二已氧基二苯甲酮的合成方法 | |
| WO2012024397A3 (en) | 2,5-methano-and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin | |
| TW200610758A (en) | Alpha crystalline form of strontium ranelate, a process for its preparation, and pharmaceutical compositions containing it | |
| CN105199017B (zh) | 一种Cs-CD-MOFs化合物及其制备方法 | |
| CN103787916B (zh) | 一种肟菌酯的制备方法 | |
| JP2020503330A5 (https=) | ||
| JP2019524829A5 (https=) | ||
| CN102763886A (zh) | 一种食品防腐剂 |